Telix Pharmaceuticals Limited (TLX)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from TLX's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Telix Pharmaceuticals Limited's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $333M | $517M | $804M |
| Net income | $4M | $34M | -$7M |
| Free cash flow | $7M | $5M | -$61M |
| EPS (diluted) | $0.01 | $0.10 | -$0.02 |
| Operating margin | 3.3% | 10.7% | 3.7% |
Where the revenue comes from
Revenue by segments, fiscal 2025. Every breakdown, year by year.
Superinvestors who own TLX
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by Telix Pharmaceuticals Limited's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Sep 7, 2026 | Darren Charlton Smith Group Chief Financial Officer |
2,071 | $9.66 | $19,998 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when TLX trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Telix Pharmaceuticals Limited insiders buying the stock?
1 open-market insider purchase of TLX in the last 12 months, from SEC Form 4 filings.
Companies like Telix Pharmaceuticals Limited
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.